Author/Authors :
H. Mignotte، نويسنده , , J.F. Rodier، نويسنده , , A. Lesur، نويسنده , , S. Hoffstetter، نويسنده , , B. Cutuli، نويسنده , , J. DʹAnjou، نويسنده , , P. Rouanet، نويسنده , , S. Lasry، نويسنده , , G. Le Bouedec، نويسنده , , J. Dauplat، نويسنده , , G. Depad، نويسنده , , S. Giard، نويسنده , , E. Fondrinier، نويسنده ,
Abstract :
Tamoxifen has been used for two decades as adjuvant therapy for breast cancer. It is also now being used to try and prevent this disease in women at high risk. A series of 89 patients who developed endometrial cancer on adjuvant has been identified from nine French cancer institutes. Although there was a high frequency of superficial, generally well-differentiated forms, some patients did have aggressive disease with a relatively poor outcome and there were 10 deaths from endometrial carcinoma. These data support gynaecological surveillance of women receiving tamoxifen therapy.
